These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 337945)

  • 1. Ocular tolerance of bacillus Calmette-Guerin organisms.
    Rutgard J; Frenkel M; Peyman GA; Saks S; Stankevych A
    Arch Ophthalmol; 1977 Dec; 95(12):2210-3. PubMed ID: 337945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calmette-Guerin bacillus treatment of experimental conjunctival malignant melanoma.
    Rutgard J; Peyman GA; Frenkel M; Saks S
    Arch Ophthalmol; 1977 Dec; 95(12):2214-7. PubMed ID: 588117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
    MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
    Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
    Dubois JB; Serrou B
    Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin and antilymphocyte serum in carcinogenesis. Effects on the hamster pouch.
    Giunta JL; Reif AE; Shklar G
    Arch Pathol; 1974 Oct; 98(4):237-40. PubMed ID: 4606260
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG; Sparks FC; Morton DL
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guérin: experimental and clinical results.
    Yamamura Y; Azuma I; Taniyama T; Sugimura K; Hirao F; Tokuzen R; Okabe M; Nakahara W; Yasumoto K; Ohta M
    Ann N Y Acad Sci; 1976; 277(00):209-27. PubMed ID: 826205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin.
    Kollmorgen GM; Killion JJ; Sansing WA; Cantrell JL; Bundren JC; LeFever AV
    Surgery; 1976 Feb; 79(02):202-8. PubMed ID: 1108258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Myobacterium bovis (strain Bacillus Calmette-Guérin) on macrophage production by the bone marrow of tumor-bearing mice.
    Fisher B; Taylor S; Levine M; Saffer E; Fisher ER
    Cancer Res; 1974 Jul; 34(7):1668-70. PubMed ID: 4599359
    [No Abstract]   [Full Text] [Related]  

  • 13. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
    Hanna MG; Peters LC
    Cancer Res; 1978 Jan; 38(1):204-9. PubMed ID: 201374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The methanol extract residue (MER) of bacillus calmette-guerin in cancer immunotherapy.
    Domenick NP
    Nurs Clin North Am; 1978 Jun; 13(2):369-80. PubMed ID: 353752
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonspecific immunotherapy of malignant tumors.
    Milas L; Withers HR
    Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size characterization of Mycobacterium bovis BCG (Bacillus Calmette Guérin) vaccine, Tice substrain.
    Zhang A; Groves MJ
    Pharm Res; 1988 Sep; 5(9):607-10. PubMed ID: 3073388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
    Liotta LA; Kleinerman J; Saidel GM
    Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
    Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.